| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Does Dusa Run Too Hard?
Posted on 05/17/2007 18:46:28 | Link | Post Comment
by Douglas A. McIntyre
24/7 Wall St.
Dusa Pharmaceuticals (DUSA) received "orphan drug status" for its for Levulan photodynamic therapy for the treatment of esophageal dysplasia, a disease that occurs in some patients with Barrett's esophagus, a leading cause of esophageal cancer. Orphan diseases are defined as diseases affecting fewer than 200,000 people in the United States or low prevalence is taken as prevalence of less than 5 per 10,000 in the community. Because it is hard to get back the investment in new drugs, the status may grant longer patent times or outside funding for research.
The news from Dusa pushed its stock up 60% to $4.40.
Continue article at 247WallSt.com
__________________
24/7 Wall St.
Dusa Pharmaceuticals (DUSA) received "orphan drug status" for its for Levulan photodynamic therapy for the treatment of esophageal dysplasia, a disease that occurs in some patients with Barrett's esophagus, a leading cause of esophageal cancer. Orphan diseases are defined as diseases affecting fewer than 200,000 people in the United States or low prevalence is taken as prevalence of less than 5 per 10,000 in the community. Because it is hard to get back the investment in new drugs, the status may grant longer patent times or outside funding for research.The news from Dusa pushed its stock up 60% to $4.40.
Continue article at 247WallSt.com
__________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Trader X
- Real Estate Marketing Blog
- Morpheus Trading
- Alpha Trends
- Millionaire Now! by Larry Nusbaum
- Random Roger's Big Picture
Examples
ATM Wallstreet - Mon Oct 06, 2008 03:39PM
Made several great trades today. Traded the QID, QQ [read more]
Made several great trades today. Traded the QID, QQ [read more]
ATM Wallstreet - Sat Oct 04, 2008 10:41PM
When I first started Day Trading I traded anything that [read more]
When I first started Day Trading I traded anything that [read more]
Morpheus Trading - Thu Oct 02, 2008 08:58AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
<< My Home | TheMoneyBlogs Home